Difference in drug resistance patterns between minor HIV-1 populations in cerebrospinal fluid and plasma

HIV Medicine

Volumn 10, Issue 2, 2009, Pages 111-115

  Bergroth, Tobias ^a   Ekici, H ^a   Gisslen M ^b   Hagberg, L ^b   Sonnerborg A ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Cerebrospinal fluid; Compartments; HIV 1; M184I V; Minor populations; Resistance; Selective real time PCR

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE PLUS LAMIVUDINE PLUS LOVIRIDE; DIDANOSINE PLUS LAMIVUDINE PLUS LOVIRIDE PLUS ZIDOVUDINE; DIDANOSINE PLUS LAMIVUDINE PLUS SAQUINAVIR PLUS STAVUDINE; EFAVIRENZ PLUS LAMIVUDINE PLUS TENOFOVIR; INDINAVIR PLUS LAMIVUDINE PLUS STAVUDINE; INDINAVIR PLUS STAVUDINE PLUS ZALCITABINE; LAMIVUDINE PLUS LOPINAVIR PLUS RITONAVIR PLUS ZIDOVUDINE; LAMIVUDINE PLUS NELFINAVIR PLUS SAQUINAVIR PLUS STAVUDINE; LAMIVUDINE PLUS NELFINAVIR PLUS STAVUDINE; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS STAVUDINE PLUS ZALCITABINE; LAMIVUDINE PLUS ZIDOVUDINE; UNCLASSIFIED DRUG;

ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MUTANT; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION; SPECIES DIFFERENCE; TREATMENT FAILURE; VIRUS LOAD; VIRUS MUTANT; WILD TYPE;

ADULT; CEREBROSPINAL FLUID; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; LAMIVUDINE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD;

EID: 68949114583     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00659.x     Document Type: Article

References (17)

1. Sönnerborg A, Ehrnst A, Bergdahl S, Pehrson P, Sköldenberg B, Strannegård O. HIV isolation from cerebrospinal fluid in relation to immunological deficiency and neurological symptoms. AIDS 1988; 2: 89-93.
2. Ellis RJ, Gamst AC, Capparelli E et al. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology 2000; 54: 927-936.
3. Yilmaz A, Svennerholm B, Hagberg L, Gisslén M. Cerebrospinal fluid viral loads reach less than 2 copies/mL in HIV-1-infected patients with effective antiretroviral therapy. Antivir Ther 2006; 11: 833-837.
4. Antinori A, Perno CF, Giancola ML et al. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: Different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis 2005; 41: 1787-1793.
5. Günthard HF, Havlir DV, Fiscus S et al. Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. J Infect Dis 2001; 183: 1318-1327.
6. Strain MC, Letendre S, Pillai SK et al. Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy. J Virol 2005; 79: 1772-1788.
7. Harrington PR, Haas DW, Ritola K, Swanstrom R. Compartmentalized human immunodeficiency virus type 1 present in cerebrospinal fluid is produced by short-lived cells. J Virol 2005; 79: 7959-7966.
8. Boucher CA, Cammack N, Schipper P et al. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1993; 37: 2231-2234.
9. Cunningham PH, Smith DG, Satchell C, Cooper DA, Brew B. Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid. AIDS 2000; 14: 1949-1954.
10. Spudich S, Lollo N, Liegler T, Deeks SG, Price RW. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis 2006; 194: 1686-1696.
11. Venturi G, Catucci M, Romano L et al. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples. J Infect Dis 2000; 181: 740-745.
12. Karlsson AC, Lindbäck S, Gaines H, Sönnerborg A. Characterization of the viral population during primary HIV-1 infection. AIDS 1998; 12: 839-847.
13. Bergroth T, Sönnerborg A, Yun Z. Discrimination of lamivudine resistant minor HIV-1 variants by selective real-time PCR. J Virol Methods 2005; 127: 100-107.
14. Gisslén M, Hagberg L, Brew BJ, Cinque P, Price RW, Rosengren L. Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex. J Infect Dis 2007; 195: 1774-1778.
15. Svedhem V, Bergroth T, Lidman K, Sönnerborg A. Presence of M184I/V in minor HIV-1 populations of patients with lamivudine and/or didanosine treatment failure. HIV Med 2007; 8: 504-510.
16. Paredes R, Marconi VC, Campbell TB, Kuritzkes DR. Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with Pol and env resistance mutations. J Virol Methods 2007; 146: 136-146.
17. Foudraine NA, Hoetelmans RM, Lange JM et al. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 1998; 351: 1547-1551.